Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record, with a small difference in title or year; 24 of the 25 references it cites were found in a registry or an index.

d -Dimer Testing to Determine the Duration of Anticoagulation Therapy

Open access

Abstract

BACKGROUND: The optimal duration of oral anticoagulation in patients with idiopathic venous thromboembolism is uncertain. Testing of D-dimer levels may play a role in the assessment of the need for prolonged anticoagulation. METHODS: We performed D-dimer testing 1 month after the discontinuation of anticoagulation in patients with a first unprovoked proximal deep-vein thrombosis or pulmonary embolism who had received a vitamin K antagonist for at least 3 months. Patients with a normal D-dimer level did not resume anticoagulation, whereas those with an abnormal D-dimer level were randomly assigned either to resume or to discontinue treatment. The study outcome was the composite of recurrent venous thromboembolism and major bleeding during an average follow-up of 1.4 years. RESULTS: The D-dimer assay was abnormal in 223 of 608 patients (36.7%). A total of 18 events occurred among the 120 patients who stopped anticoagulation (15.0%), as compared with 3 events among the 103 patients who resumed anticoagulation (2.9%), for an adjusted hazard ratio of 4.26 (95% confidence interval [CI], 1.23 to 14.6; P=0.02). Thromboembolism recurred in 24 of 385 patients with a normal D-dimer level (6.2%). Among patients who stopped anticoagulation, the adjusted hazard ratio for recurrent thromboembolism among those with an abnormal D-dimer level, as compared with those with a normal D-dimer level, was 2.27 (95% CI, 1.15 to 4.46; P=0.02). CONCLUSIONS: Patients with an abnormal D-dimer level 1 month after the discontinuation of anticoagulation have a significant incidence of recurrent venous thromboembolism, which is reduced by the resumption of anticoagulation. The optimal course of anticoagulation in patients with a normal D-dimer level has not been clearly established. (ClinicalTrials.gov number, NCT00264277 [ClinicalTrials.gov].).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa054444

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Research works printed but not linked: 1

  1. Kearon C, 2003, CMAJ, 168, 183

Cited by

See all 622

Metadata

Authors
Palareti, G., Cosmi, B., Legnani, C., Tosetto, A., Brusi, C., Iorio, A., Pengo, V., Ghirarduzzi, A., Pattacini, C., Testa, S., Lensing, A. W. A., & Tripodi, A.
Affiliations
  • IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
  • Ospedale San Bortolo (IT)
  • University of Perugia (IT)
  • Azienda Ospedale - Università Padova (IT)
  • Santa Maria Nuova Hospital (IT)
  • Istituti Ospitalieri di Cremona (IT)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
Venue
New England Journal of Medicine
Published
2006-10-26
Volume
355
Issue
17
Pages
1780-1789
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2047986798
Cited by
622
References
25
Citations by year
2026: 10 · 2025: 16 · 2024: 12 · 2023: 11 · 2022: 14 · 2021: 16 · 2020: 34 · 2019: 22 · 2018: 20 · 2017: 19 · 2016: 40 · 2015: 41 · 2014: 40 · 2013: 38 · 2012: 53
FWCI
35.51
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Health Sciences › Medicine › Clinical Neurology › Cerebral Venous Sinus Thrombosis
Keywords
D-dimer, anticoagulation duration, venous thromboembolism, deep vein thrombosis, pulmonary embolism, vitamin K antagonists, recurrence, major bleeding, unprovoked thrombosis, anticoagulation resumption
MeSH terms
Acenocoumarol, Adult, Aged, Aged, 80 and over, Anticoagulants, Antithrombins, Drug Administration Schedule, Fibrin Fibrinogen Degradation Products, Follow-Up Studies, Hemorrhage, Humans, Middle Aged, Prospective Studies, Pulmonary Embolism, Recurrence, Ultrasonography, Vitamin K, Warfarin, Proportional Hazards Models, Survival Analysis, Antiphospholipid Syndrome, Venous Thrombosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.